Download PDF
Der Nuklearmediziner 2002; 25(3): 181-185
DOI: 10.1055/s-2002-34105
Dopaminerges System

© Georg Thieme Verlag Stuttgart · New York

Untersuchungen mit der Positronen-Emissions-Tomographie (PET) bei Patienten mit Morbus Parkinson

PET-Studies in Parkinson's DiseaseJ. Schwarz
  • Klinik für Neurologie, Universität Leipzig
Further Information

Publication History

Publication Date:
16 September 2002 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Positronen-Emissions-Tomographie (PET) bietet neben der Messung von Metabolismus und Blutfluss die Möglichkeit der Darstellung von einzelnen Molekülen. Bei Patienten mit Morbus Parkinson hat es diese Technik erstmals erlaubt, die Anzahl der dopaminergen Neurone zu quantifizieren, wodurch die Diagnose gesichert, die Progression der Erkrankung beurteilt und auch das Anwachsen von Implantaten beurteilt werden kann. Die PET hat einen wesentlichen Beitrag zu unserem heutigen Wissen über die Pathophysiologie dieser Erkrankung beigetragen.

Abstract

Positron-Emission-Tomography (PET) has enabled to study the metabolism and blood flow in specific brain areas. Besides, there is a variety of radiotracers that allow quantification of the function of distinct molecules. In respect to Parkinson's disease, PET allowed for the first time to assess the number of dopaminergic neurons in vivo.
Thus, helping confirming a dopaminergic deficit, measuring disease progression and also help to determine the function of dopaminergic grafts. Current research has shifted to determine the role of related neurotransmitter systems in the pathophysiology of Parkinson's disease.

Schlüsselwörter

PET - Parkinson - FDOPA

Key words

PET - Parkinson - FDOPA

Literatur

  • 1 Antonini A, Moeller J R, Nakamura T, Spetsieris P, Dhawan V, Eidelberg D. The metabolic anatomy of tremor in Parkinson's disease.  Neurology. 1998;  51 803-810
    PubMedSearch in Google Scholar
  • 2 Antonini A, Schwarz J, Oertel W H, Beer H F, Madeja U D, Leenders K L. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.  Neurology. 1994;  44 1325-1329
    PubMedSearch in Google Scholar
  • 3 Antonini A, Schwarz J, Oertel W H, Pogarell O, Leenders K L. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.  Mov Disord. 1997;  12 33-38
    CrossrefPubMedSearch in Google Scholar
  • 4 Brooks D J. PET studies on the early and differential diagnosis of Parkinson's disease.  Neurology. 1993;  43 6-16
    PubMedSearch in Google Scholar
  • 5 Brooks D J, Piccini P, Turjanski N, Samuel M. Neuroimaging of dyskinesia.  Ann Neurol. 2000;  47 154-158 discussion 158-159
    PubMedSearch in Google Scholar
  • 6 Brooks D J, Samuel M. The effects of surgical treatment of Parkinson's disease on brain function: PET findings.  Neurology. 2000;  55 52-59
    PubMedSearch in Google Scholar
  • 7 Ceballos-Baumann A O, Boecker H, Bartenstein P, von Falkenhayn I, Riescher H, Conrad B, Moringlane J R, Alesch F. A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity.  Arch Neurol. 1999;  56 997-1003
    CrossrefPubMedSearch in Google Scholar
  • 8 Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years.  Nucl Med Commun. 2001;  22 721-725
    CrossrefPubMedSearch in Google Scholar
  • 9 Duffau H, Tzourio N, Caparros-Lefebvre D, Parker F, Mazoyer B. Tremor and voluntary repetitive movement in Parkinson's disease: comparison before and after L-dopa with positron emission tomography.  Exp Brain Res. 1996;  107 453-462
    PubMedSearch in Google Scholar
  • 10 Eidelberg D, Moeller J R, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S. et al . The metabolic topography of parkinsonism.  J Cereb Blood Flow Metab. 1994;  14 783-801
    CrossrefPubMedSearch in Google Scholar
  • 11 Eidelberg D, Moeller J R, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, Belakhlef A, Mandel F, Przedborski S, Fahn S. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography.  Neurology. 1995;  45 1995-2004
    PubMedSearch in Google Scholar
  • 12 Feigin A, Fukuda M, Dhawan V, Przedborski S, Jackson-Lewis V, Mentis M J, Moeller J R, Eidelberg D. Metabolic correlates of levodopa response in Parkinson's disease.  Neurology. 2001;  57 2083-2088
    PubMedSearch in Google Scholar
  • 13 Fukuda M, Mentis M, Ghilardi M F, Dhawan V, Antonini A, Hammerstad J, Lozano A M, Lang A, Lyons K, Koller W, Ghez C, Eidelberg D. Functional correlates of pallidal stimulation for Parkinson's disease.  Ann Neurol. 2001;  49 155-164
    CrossrefPubMedSearch in Google Scholar
  • 14 Fukuda M, Mentis M J, Ma Y, Dhawan V, Antonini A, Lang A E, Lozano A M, Hammerstad J, Lyons K, Koller W C, Moeller J R, Eidelberg D. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism.  Brain. 2001;  124 1601-1609
    CrossrefPubMedSearch in Google Scholar
  • 15 Guttman M, Burkholder J, Kish S J, Hussey D, Wilson A, DaSilva J, Houle S. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold.  Neurology. 1997;  48 1578-1583
    PubMedSearch in Google Scholar
  • 16 Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.  Neurology. 2001;  56 1559-1564
    PubMedSearch in Google Scholar
  • 17 Holthoff V A, Vieregge P, Kessler J, Pietrzyk U, Herholz K, Bonner J, Wagner R, Wienhard K, Pawlik G, Heiss W D. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits.  Ann Neurol. 1994;  36 176-182
    CrossrefPubMedSearch in Google Scholar
  • 18 Kaasinen V, Nurmi E, Bruck A, Eskola O, Bergman J, Solin O, Rinne J O. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex.  Brain. 2001;  124 1125-1130
    CrossrefPubMedSearch in Google Scholar
  • 19 Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, Neumeyer J, Eidelberg D. Dopamine transporter imaging with fluorine-18-FPCIT and PET.  J Nucl Med. 1998;  39 1521-1530
    PubMedSearch in Google Scholar
  • 20 Laihinen A O, Rinne J O, Ruottinen H M, Nagren K A, Lehikoinen P K, Oikonen V J, Ruotsalainen U H, Rinne U K. PET studies on dopamine D1 receptors in the human brain with carbon-11- SCH 39 166 and carbon-11-NNC 756.  J Nucl Med. 1994;  35 1916-1920
    PubMedSearch in Google Scholar
  • 21 Leenders K L, Herold S, Brooks D J, Palmer A J, Turton D, Firnau G, Garnett E S, Nahmias C, Veall N. Pre-synaptic and post-synaptic dopaminergic system in human brain.  Lancet. 1984;  2 110-111
    PubMedSearch in Google Scholar
  • 22 Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, Leenders K L, Sawle G, Rothwell J C, Marsden C D. et al . Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease.  Science. 1990;  247 574-577
    PubMedSearch in Google Scholar
  • 23 Lindvall O, Hagell P. Cell therapy and transplantation in Parkinson's disease.  Clin Chem Lab Med. 2001;  39 356-361
    CrossrefPubMedSearch in Google Scholar
  • 24 Morrish P K, Rakshi J S, Bailey D L, Sawle G V, Brooks D J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.  J Neurol Neurosurg Psychiatry. 1998;  64 314-319
    CrossrefPubMedSearch in Google Scholar
  • 25 Morrish P K, Sawle G V, Brooks D J. Clinical and [18F] dopa PET findings in early Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1995;  59 597-600
    CrossrefPubMedSearch in Google Scholar
  • 26 Morrish P K, Sawle G V, Brooks D J. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.  Brain. 1996;  119 585-591
    PubMedSearch in Google Scholar
  • 27 Nurmi E, Bergman J, Eskola O, Solin O, Hinkka S M, Sonninen P, Rinne J O. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.  J Cereb Blood Flow Metab. 2000;  20 1604-1609
    PubMedSearch in Google Scholar
  • 28 Nurmi E, Ruottinen H M, Kaasinen V, Bergman J, Haaparanta M, Solin O, Rinne J O. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.  Ann Neurol. 2000;  47 804-808
    CrossrefPubMedSearch in Google Scholar
  • 29 Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain.  Prog Neurobiol. 2000;  61 75-111
    CrossrefPubMedSearch in Google Scholar
  • 30 Piccini P, Brooks D J. Etiology of Parkinson's disease: contributions from 18F-DOPA positron emission tomography.  Adv Neurol. 1999;  80 227-231
    PubMedSearch in Google Scholar
  • 31 Piccini P, Brooks D J, Bjorklund A, Gunn R N, Grasby P M, Rimoldi O, Brundin P, Hagell P, Rehncrona S, Widner H, Lindvall O. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient.  Nat Neurosci. 1999;  2 1137-1140
    CrossrefPubMedSearch in Google Scholar
  • 32 Piccini P, Weeks R A, Brooks D J. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.  Ann Neurol. 1997;  42 720-726
    CrossrefPubMedSearch in Google Scholar
  • 33 Rascol O, Sabatini U, Chollet F, Fabre N, Senard J M, Montastruc J L, Celsis P, Marc-Vergnes J P, Rascol A. Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa.  J Neurol Neurosurg Psychiatry. 1994;  57 567-571
    PubMedSearch in Google Scholar
  • 34 Rinne J O, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1999;  67 737-741
    CrossrefPubMedSearch in Google Scholar
  • 35 Sawle G V, Playford E D, Burn D J, Cunningham V J, Brooks D J. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F18 positron emission tomography data.  Arch Neurol. 1994;  51 237-243
    PubMedSearch in Google Scholar
  • 36 Schwarz J, Antonini A, Tatsch K, Kirsch C M, Oertel W H, Leenders K L. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism.  Nucl Med Commun. 1994;  15 806-813
    PubMedSearch in Google Scholar
  • 37 Schwarz J, Linke R, Kerner M, Mozley P D, Trenkwalder C, Gasser T, Tatsch K. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis.  Arch Neurol. 2000;  57 205-208
    CrossrefPubMedSearch in Google Scholar
  • 38 Schwarz J, Oertel W H, Tatsch K. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa.  J Nucl Med. 1996;  37 1112-1115
    PubMedSearch in Google Scholar
  • 39 Schwarz J, Tatsch K, Arnold G, Ott M, Trenkwalder C, Kirsch C M, Oertel W H. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism.  Neurology. 1993;  43 17-20
    PubMedSearch in Google Scholar
  • 40 Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel W H. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.  Mov Disord. 1997;  12 898-902
    CrossrefPubMedSearch in Google Scholar
  • 41 Schwarz J, Tatsch K, Gasser T, Arnold G, Pogarell O, Kunig G, Oertel W H. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.  Mov Disord. 1998;  13 16-19
    CrossrefPubMedSearch in Google Scholar
  • 42 Turjanski N, Lees A J, Brooks D J. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.  Neurology. 1997;  49 717-723
    PubMedSearch in Google Scholar
  • 43 Verhoeff N P. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders.  Psychopharmacology (Berl). 1999;  147 217-249
    CrossrefPubMedSearch in Google Scholar
  • 44 Vingerhoets F J, Snow B J, Lee C S, Schulzer M, Mak E, Calne D B. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.  Ann Neurol. 1994;  36 759-764
    CrossrefPubMedSearch in Google Scholar
  • 45 Volkow N D, Fowler J S, Ding Y S, Wang G J, Gatley S J. Positron emission tomography radioligands for dopamine transporters and studies in human and nonhuman primates.  Adv Pharmacol. 1998;  42 211-214
    PubMedSearch in Google Scholar

Prof. Dr. Johannes Schwarz

Klinik und Poliklinik für Neurologie

Universitätsklinikum Leipzig

Liebigstr. 22 a

04103 Leipzig

Phone: +49/3 41/9 72 42 02

Fax: +49/3 41/9 72 42 39

Email: tetu@medizin.uni-leipzig.de